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Protective action of glycine in cisplatin nephrotoxicity. Because glycine
is cytoprotective for kidney cells in vitro, we investigated its possible
action in vivo to protect rats against cisplatin nephrotoxicity, a well-
established experimental model of renal tubular injury. Glycine was
infused at a dose of I mmol per 100 g body weight per hour for 75
minutes, starting 15 minutes before cisplatin, 5 mg per kg, was injected
intravenously. Plasma concentration of glycine rose to 3.5 mmol per
liter at the time cisplatin was injected. These rats were compared with
cisplatin-treated animals treated with L-alanine or with isotonic saline.
After five days plasma creatinine of saline-treated rats given cisplatin
had risen threefold to 2.6 1.5 mg per 100 ml (mean SD), as
creatinine clearance fell to 25% of baseline (0.14 0.05 ml/min/I00 g).
Morphological evaluation disclosed extensive damage involving all S3
segments in the outer medulla as well as the medullary rays of the
cortex. In contrast, in rats treated with glycine, plasma creatinine rose
only to 1.2 0.2 mg/lOO ml and creatinine clearance was maintained at
75% of baseline (0.35 0.05 ml/min/l00 g). Glycine also attenuated the
weight loss, polyuria, increased fractional excretion of sodium and
potassium, decreased urinary osmolality, and renal glycosuria observed
in control, saline-treated rats after cisplatin, while substantially de-
creasing the percentage of S3 tubules with evident morphological
injury. Renal platinum content was unaffected by glycine. The admin-
istration of L-alanine or the delayed infusion of glycine, starting one
hour after cisplatin was given, did not prevent cisplatin toxicity. Thus,
high plasma concentrations of glycine achieved during a brief period of
time when cisplatin is administered, markedly attenuate cisplatin neph-
rotoxicity.
Glycine provides remarkable protection against anoxic injury
[1, 2] and ouabain toxicity [3] in dispersed rabbit proximal
tubules incubated in vitro. Hypoxic injury to medullary thick
ascending limbs is prevented by glycine in the isolated perfused
rat kidney [4, 5], as is the outer medullary damage from
indomethacin and amphotericin in the same experimental model
[4]. Systemic infusion of glycine also appears to maintain
proximal tubular function following intratubular application of
uranyl nitrate [6].
The dosage of cisplatin, a potent, wide spectrum drug utilized
in solid tumor chemotherapy, is limited by its renal and neural
toxicity. The incidence of deterioration in renal function is high,
around 20%, in spite of the use of low divided doses, prolonged
infusion periods, saline hydration and diuretics [7]. In the
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present study we show that the administration of glycine
ameliorates tubular injury and renal dysfunction in rats treated
with cisplatin.
Methods
General
Male Sprague-Dawley rats weighing 210 to 330 g were used
for all experiments. They were given regular chow and tap
water ad libitum. Under pentobarbital anesthesia (65 mg/kg) the
right jugular vein was cannulated with two polyethylene tubes
(PE-SO, Clay-Adams, Parsippany, New Jersey, USA) for the
infusion of cisplatin and amino acids. The rats were kept in
heated chambers (37°C) throughout the experiment. At the end
of the infusion period, the cannulas were removed, the rats
were allowed to recover, and were observed over the next five
days.
Experimental groups
Four groups of cisplatin-treated rats were examined: I)
glycine-treated rats (GLY, N = 16); 2) L-alanine-treated rats
(ALA, N = 6); 3) rats with late initiation of glycine infusion
(D-GLY, N = 6); 4) a control group of saline-treated rats (CTR,
N = 20).
Cisplatin injection
A total of 5 mg/kg cisplatin was injected over 60 seconds
through a jugular cannula. A preparation used in clinical prac-
tice (Platinol, Bristol-Myers Co., Evansville, Iowa, USA) was
dissolved in distilled water, so that each milliliter contained 1.67
mg cisplatin, 16.7mg of mannitol and 15 mg of sodium chloride.
Amino acid infusion
Glycine was infused at a rate of 75 mg (1 mmol) per 100 g
body weight, in 1.06 ml saline per hour. L-alanine was given in
an equimolar dose (89 mg/tOO grams body wt/l .56 ml saline/hr).
(The difference in solute volume resulted from the lower
solubility of alanine.) Control rats were given 1.06 ml saline/hr.
In the GLY, ALA and CTR groups, infusion was initiated 15
minutes before the cisplatin injection through the second can-
nula, and was carried out for 75 minutes. In the D-GLY group
a 75-minute glycine infusion was started one hour after the
injection of cisplatin.
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Functional studies
The rats were kept in metabolic cages (Nalge Co., Rochester,
New York, USA) for the evaluation of kidney function. Twen-
ty-four-hour urine collections initiated at 10 a.m. were carried
out at baseline (day 0), during the first 24 hours following the
cisplatin injection (day 1), and on day 5. Corresponding 0.8 ml
blood samples were withdrawn from the right femoral vein at
the end of each collection period, consisting of a baseline
sample taken during the pentobarbital anesthesia, a sample at
day 2 under light ether anesthesia, and another at the end of the
experiment on day 6. Measurements of sodium and potassium
were done with ion selective electrodes (Beckman Lablyte 800,
Brea, California, USA). Plasma magnesium was measured by
atomic absorption spectrometer (Perkin-Elmer 303, Norwalk,
Connecticut, USA). Creatinine and plasma glucose were quan-
tified by colorimetric reactions (Abbot 100 Biochromatic Ana-
lyzer, S. Pasadena, California, and COBAS Bio, Roche Diag-
nostic Systems, Nutley, New Jersey, USA, respectively).
Glycosuria was estimated semi-quantitatively using urine Test-
strips (Boehringer Mannheim Diagnostics, Indianapolis, Indi-
ana, USA). Urine osmolarity was measured by a freezing point
osmometer (uosmette 5004, Precision Systems, Natick, Massa-
chusetts, USA).
Morphologic evaluation
The rats were anesthetized at day 6 with mactin 100 mg/kg
(BYK Gulden Konstanz, Germany). A midline abdominal inci-
sion was performed, the right renal pedicle clamped and the
kidney removed for cisplatin measurements. Heparin (400 U)
was injected intravenously and the left kidney was perfusion-
fixed in situ with 1.25% glutaraldehyde (Eastman Kodak Co.,
Rochester, New York, USA) in 0.1 M phosphate buffer (pH 7.4)
through a 19 gauge needle inserted in the aorta. Perfusion
pressure was kept at 130 mm Hg, and the superior mesenteric
artery and the aorta above and below the renal artery were
clamped to provide optimal fixation. The kidneys were sec-
tioned and postfixed in buffered 2% 0s04, dehydrated and
embedded in an Araldit-Epon B12 mixture. Three x 3 mm I am
sections containing cortex and outer medulla were cut. The
sections were stained with 1% methylene blue and examined by
light microscopy in a blinded fashion (interpreted by the exam-
iner without knowing the study groups).
A semiquantitative morphological analysis of proximal
straight (S3) tubular damage, the characteristic morphological
feature of cisplatin nephrotoxicity [8], was performed, using the
following categories: 0 = no damage; 1+, 2+, 3+ 25%, 50%
and 100% outer stripe S3 injury, respectively. Intermediate
degrees of injury were also designated. Complete outer stripe
destruction, extending beyond this region to involve S3 seg-
ments in the medullary rays, was ranked as 4+ and was
considered as 125% necrotic proximal tubules for the data
analysis. Data were eventually converted to a percentage of
examined tubules evincing injury.
Platinum measurement
This was carried out in rats from the CTR and GLY groups,
chosen at random, five from each group. Plasma samples from
days 2 and 6 and samples of urine collected during the first 24
hours after cisplatin were examined (collection period started 2
h after cisplatin injection). The right kidney, removed at day 6,
was weighed and frozen. All specimens were analyzed in
duplicate for platinum with a Perkin Elmer model 1100 atomic
absorption spectrometer, as described elsewhere [9].
Glycine concentrations
Continuous infusion of glycine, 75 mg/lOO g body weight in
1.56 ml per hour was carried out for 90 minutes in two rats.
Repeated blood samples with EDTA were taken during the
infusion period, quickly centrifuged and the plasma collected
and frozen. At the end of the infusion period the kidneys and
liver slices were quickly removed, weighed, washed in iced
saline and homogenized in 5% trichloroacetic acid. Samples
were centrifuged and the supernatant was titrated with NaOH
to pH 7. Amino acid assay was performed on the plasma and
tissue samples using the Water's Pico-Tag method [10]. Cali-
bration was based on a 200 mM/I standard.
Statistics
Values in Figures and Tables are presented as the means SE
or SD, respectively. Non-paired two-tailed Student's t-test was
applied for the comparisons of platinum content. One or two-
way analysis of variance with Newman Keuls test were used for
multiple comparisons between and within groups, as detailed
below. Baseline values were utilized as covariates for compar-
isons of repeated measurements within groups. Simple correla-
tions were calculated between functional and morphologic
findings in the various experimental groups. Statistical signifi-
cance was set at P < 0.05.
Results
Effrct of cisplatin on renal function and structure
All control rats given cisplatin without amino acids developed
marked structural damage, usually involving the entire S3
segments in the outer stripe of the outer medullary zone, with
lesions extending to the medullary rays (Fig. 1A, Table 1).
Renal function deteriorated over five days, with more than a
threefold increase in plasma creatinine, from 0.8 0.1 to 2.6
1.5 mg/l00 ml (mean SD, P <0.002, paired Student's t-test),
and a drop in creatinine clearance to about one-fourth of
baseline values (from 0.48 0.1 to 0.14 0.05 mllmin/100 g
weight, P < 0.005; Table 1). Glycosuria developed in all rats,
averaging 22! 105 mg per 100 ml on the fifth day after
cisplatin injection. Renal glycosuria was confirmed by normal
plasma glucose levels (119 36 mg per 100 ml). Polyuria with
reduced urinary osmolality developed, urine volume rising to
2.29 1.62 from 0.56 0.14 mI/hr. and urinary osmolality
falling from 1943 275 to 425 137 mOsm (Fig. 2). Fractional
sodium and potassium excretions increased (P < 0.05) and a
substantial decrease in body weight was noted (Table 1, Figs. 2
and 3). The volume of urine excreted by glycine-treated rats
during their 75 minute infusion of glycine and cisplatin (1.1
0.1 ml) did not differ from that excreted by control rats
receiving cisplatin with saline vehicle (0.9 0.1 ml).
Effect of amino acids on injury induced by cisplatin
In contrast to the findings in the control rats, renal injury was
markedly attenuated by simultaneous administration of glycine.
Proximal tubular injury was limited to 40% of tubules examined
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Fig. I. Rats given dsp/atm (5 mg/kg) and sacr(/Iced five days later. These photographs are of the outer stripe of the outer medulla, where the
cellular mass largely consists of straight (S3) segments of the proximal tubules. In control animals (CTR) typically all S3 segments in this zone show
injury (A) that is markedly diminished in glycine treated rats (GLY) (B). At high power (C) injured S3 segments seem to be lined by a thin layer
of regenerating epithelium (asterisks). Note the medullary thick ascending limb (T) and collecting duct (D) that are undamaged. (Methylene blue,
x64; X64; x500)
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Table 1. Effects of glycine and alanine on cisplatin nephrotoxicity
Plasma creatinine Creatinine clearance Fractional excretion of Na S3 injury
Group
(N)
mg/100 ml ml/min/IOO g °'° Weight loss
% of initial weight Day 6Day 1 Day 6 Day 0 Day 5 Day 0 Day 5
Control (20) 0.8 0.1 2.6 1.? 0.48 0.01 0.14 0.05k 0.54 0.12 1.92 1•36b 15 8 104 9
Glycine (l6) 0.8 0.1 1.2 0.2 0.51 0.11 0.35 0,05t( 0.38 0.22 0.66 0.24 4 7C 40 24d
Glycine-delayed (6) 0.8 0.1 1.7 0.4a 0.39 0.08 0.21 O.O6 0.50 0.10 1.80 081b 8 6 102 5
Alanine (6) 0.8 0.1 2.2 0.7a 0.45 0.03 0.16 O.O4 0.40 0.16 2.00 0.60k' 9 7 100 0
Values are mean SD. Two-way ANOVA is used for the comparisons of repeated functional measurements within and between the experimental
groups. One-way ANOVA is used for the comparisons of tubular injury and weight loss between groups.
a Significantly different from Day I (P < 0.01)b Significantly different from Day I (P < 0.05)
C Significantly different from Control (P < 0.01)d Significantly different from all other groups (P < 0.01)
e N = 6 for creatinine clearance and fractional excretion of Na
(Fig. lB. Table 1). The increase in plasma creatinine was less
marked than in controls (levels rising from 0.8 0.1 to 1.2 0.2
mg/l00 ml), and creatinine clearance decreased by only 38%
(Table 1). Similarly, alterations in renal electrolyte and water
handling were markedly attenuated and weight reduction was
minimized (Table I, Figs. 2 and 3). Glycosuria was minimal or
absent, averaging only 17 20 mg/100 ml on day 5. Similar
results were obtained whether glycine and cisplatin were in-
fused into the same vein or into different veins.
When glycine infusion was initiated an hour after the injec-
tion of cisplatin (D-GLY), the protective effect was almost
entirely abolished. Administration of an equimolar dose of
L-alanine (ALA) had no effect on the extent of injury and
functional derangement (Table 1, Figs. 2 and 3).
Preservation of tubular structure with glycine was also noted
in additional studies in which the cisplatin dose was 3.5 mg/kg.
In these experiments S3 tubular damage was markedly reduced
by glycine (14 26% as compared to 92 17% in controls, N
15 and 23, respectively) but not by L-alanine or glutamine (97
9%, N = 6, and 92 15%, N = 8, respectively, P < 0.01 by
one-way ANOVA).
Morphological injury was correlated with plasma creatinine (r
= 0.6, P < 0.003), creatinine clearance (r = —0.8, P < 0.001)
and urinary osmolality (r = 0.8, P < 0.001) on day 5 in those
animals studied.
Concentrations of platinum in plasma, urine and kidneys
Plasma concentration of platinum was slightly lower on day 6
in glycine-treated rats, as compared to controls (Table 2). The
concentration of platinum found in kidney tissues on day 6 was
similar in both groups, as were plasma concentrations 24 hours
after injection and urinary content of platinum on day 1. No
correlation was found between renal platinum content and the
degree of functional and structural damage.
Plasma and kidney concentrations of glycine
Plasma glycine concentration increased 40-fold from basal
values of 159 and 190 smol/liter in two rats over 60 minutes of
infusion. At 15 minutes (when cisplatin was injected in the
study groups) plasma concentrations were 3.4 and 3.6 mmol/
liter, comparable to the levels (2 mM) found to be protective in
earlier studies of isolated perfused kidneys [4, 5]. Kidney
glycine concentrations (12.3 and 6.0 j.tmollg wet wt) and liver
concentrations (8.9 and 6.8 smol/g wet wt) following 90 minutes
of infusion were similar to extrapolated plasma concentrations
at that time.
Cisplatin-induced hypokalemia
Prominent hypokalemia was noted in all experimental groups
24 hours after the platinum injection (Fig. 3A). The initial
decline in urinary potassium excretion (Fig. 3C) may reflect in
part the decrease in intake of food that was documented.
Fractional potassium excretion increased in all groups in spite
of the hypokalemia, perhaps reflecting impaired renal tubular
function (Fig. 3B). For comparison, in a group of four normal
rats starved for 24 hours, fractional excretion and total daily
urinary potassium were reduced by 62% and 44%, respectively,
while plasma potassium declined by only 8%. Plasma magne-
sium did not fall, but rather increased in the ALA, D-GLY and
CTR groups from 1.25 0.16 and 1.24 0.12 mEq/liter on day
1 and 2 to 1.81 0.19 mEq/liter on day 6 (P < 0.01, 1 way
ANOVA).
Discussion
Recently, glycine has been shown to provide protection
against certain hypoxic [1, 2] and metabolic [3] insults in
dispersed proximal tubules incubated in vitro. Glycine also
improves renal function and reduces hypoxic injury to medul-
lary thick limbs in isolated perfused rat kidneys [4, 5]. In the
present experiments carried out in vivo, glycine substantially
attenuated morphological and functional damage to the kidneys
caused by the administration of cisplatin to intact rats. The dose
of glycine administered produced plasma concentrations in the
same range as those shown to be protective in earlier experi-
ments in vitro. Equimolar L-alanine, which partially amelio-
rates damage in isolated perfused kidneys [4, 51 and proximal
tubular cells [2, 3, 11], failed to provide protection in our
experiments.
In rats and mice, cisplatin causes a dose-related, cumulative
injury most marked in the straight portion of the proximal
tubule (S3) located in the outer medulla and the medullary rays
[7, 12]. Injury to the thick ascending limb, while overshadowed
by the prominent morphological disruption of S3 cells, can be
inferred from the decrease in urinary concentrating ability [13],
renal magnesium wasting [14], and marked reduction in urinary
excretion of epidermal growth factor, which is contained exclu-
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Fig. 3. Plasma potassium levels (A), fractional potassium excretion
(B) and daily potassium excretion (C) in rats injected with cisplatin 5
mg/kg, with simultaneous infusion of saline (O—O, CTR), glycine(—A, GLY) or L-a!anine (• •, ALA), or with a delayed glycine
infusion (A—A, D-GLY). Remarkable hypokalemia was noted in all
groups as early as 24 hours after the injection of cisplatin, and persisted
at 5 days. Symbols indicate mean s; N = 6 except for plasma
potassium in GLY and CTR groups where N = 8 and 12, respectively.
Plasma potassium fell after cisplatin in all rats (# P < 0.01 vs. baseline
in all groups by two-way ANOVA). Fractional potassium excretion
significantly increased in all groups. The high total daily potassium
excretion at day 5 in the GLY group probably reflects increased intake,
as indicated by minimal weight loss as seen in Table 2. (*P < 0.0lvs.
other groups by one-way ANOVA).
increase both in size and number. Progressive azotemia evolves
over 3 to 10 days following drug administration accompanied by
more advanced mitochondrial dysfunction [17]. Altered tubular
0 1 5
Time, days
99
98
97
Fig. 2. Changes in urinary volume, osmolality and fractional tubular
reabsorption of sodium after cisplatin, in rats given saline (O—O,
CTR), L-alanine (• •, ALA), glycine (L—, GLY), or a delayed
glycine infusion (A—A, D-GLY). Data are mean SE, N = 6 for all
groups. The changes from day 0 to day 5 in urine volume, urine
osmolality and fractional tubular reabsorption of sodium are significant
in all groups (P < 0,05 by one-way ANOVA) with the exception of an
unchanged tubular sodium reabsorption in GLY rats. In this group, as
well, changes in urine osmolality and volume were less marked. (*
indicates P < 0.01 vs. other groups on day 5, by one-way ANOVA).
sively in this nephron segment [15]. Mitochondrial dysfunction
is an early event demonstrated within 20 minutes of exposure of
renal tubules to the drug [16]. Ultrastructural analysis reveals
early mitochondrial swelling, and thinning and loss of brush
borders. The basement membrane becomes electron dense and
thickened. Nuclear chromatin is condensed, and lysosomes
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Table 2. Platinum levels in plasma, urine and kidney
Group
Control
(N = 5)
Glycine(N = 5)
Plasma platinum day 2 0.44 0.04 0.39 0.07
pg/ml
Plasma platinum day 6 0.11 0.02 0.08 0.Ola
sg/ml
Kidney platinum day 6 6.80 1.11 6.40 0.76
.ig/g wet wt
Urine platinum day 1 105 156 90 126
g/24 hrs
Values are mean SD.
a p < 0.02 vs. control, by non-paired Student's f-test.
transport leads to polyuria and losses of sodium chloride,
potassium and magnesium [7, 12, 18—20].
Cisplatin is predominantly excreted by the kidney. Some 50%
of injected cisplatin is excreted in the urine over the first 24
hours in the free, unbound form [21]. Urinary excretion of
platinum rapidly diminishes subsequently, owing to its binding
by plasma proteins and deposition in tissues. The kidney retains
platinum to a greater extent than any other organ. Renal
platinum accumulation in the rat is completed over the first six
hours, and at 24 hours some 1% of an injected dose of 5 mg/kg
dose is found in the renal parenchyma.
The biochemical and subcellular basis for renal toxicity from
cisplatin is not fully understood. It is presumed that the high
platinum concentration at the corticomedullary junction of the
kidney results from active tubular transport. Low intracellular
chloride ion concentration is thought to lead to a conversion of
cisplatin to a toxic nucleophilic complex [7]. Because it is
rapidly bound to plasma and tissue proteins, it is likely that the
process of cell injury is initiated during the first minutes after
the injection of cisplatin into the bloodstream.
In this perspective, the protective effect of glycine, given
early over a brief period of time, is instructive. High plasma and
parenchymal glycine levels are apparently required at the same
time that platinum is injected in order to prevent kidney
damage, as delayed glycine administration was found to be far
less effective. It is noteworthy that glycine did not affect the
content of platinum in the kidneys of rats given cisplatin, nor
did it alter the concentration of platinum in plasma and urine,
measured 24 hours after the cisplatin administration. Glycine
might conceivably change the binding of free cytosolic plati-
num, inactivate toxic platinum species [22], or augment their
lysosomal accumulation [23]. An interaction between cisplatin
and glycine before mixing occurred in the circulation seems
unlikely, since the administration of both agents through dif-
ferent veins (jugular and femoral) did not alter the results.
The mechanism of glycine-induced protection is obscure.
Glycine and L-alanine do not reduce the utilization of oxygen
by renal tubular cells [4, 5] and do not affect ATP stores [2, 11,
24]. Weinberg et al suggested that glycine, serving as a sub-
strate for glycine N-acyltransferase, might prevent secondary
cell destruction by neutralizing free fatty acids elaborated from
damaged membranes [1], but there is as yet no direct evidence
for this hypothesis. Glycine protection apparently occurs with-
out substantial metabolism of the amino acid [11, 25].
It seems possible that the protective effect of glycine may be
related to its three-dimensional structure, as certain glycine
analogs that bind to glycine receptors in the central nervous
system have recently been found to protect against renal cell
injury in a manner similar to that of glycine [25, 26].
Hypokalemia has been reported as an uncommon complica-
tion of cisplatin treatment, and is usually attributed to hypo-
magnesemia [14, 27, 29, 30]. In the present experiments, serum
potassium fell by about 1 mEq/liter, to 3.8 0.2 during the first
24 hours after cisplatin administration, and further decreased to
3.1 0.2 over the next four days. A similar degree of hypokale-
mia was seen in animals treated with glycine. The hypokalemia
cannot be attributed to hypomagnesemia, as magnesium levels
actually increased in the ALA, D-GLY and CTR groups,
probably as a result of advanced renal failure. Though de-
creased intake of food probably contributed to a negative
potassium balance, renal potassium losses presumably also
played a role in inducing and perpetuating hypokalemia, as
indicated by the failure of fractional excretion of potassium to
fall and, indeed, its progressive increase from day 2 to day 5.
In summary, glycine infusions given to rats during the admin-
istration of cisplatin remarkably attenuates nephrotoxicity, as
assessed by kidney morphology and function. L-alanine, on the
other hand, was not effective in blunting cisplatin toxicity.
Further studies are required to evaluate the clinical importance
of this observation and to elucidate the mechanisms involved in
the protective effect of glycine.
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